Status:
RECRUITING
Efficacy Evaluation of 5-Fluorouracil as an Adjuvant to Endoscopic Dacryocystorhinostomy in Managing Primary Acquired Nasolacrimal Duct Obstruction With Small Lacrimal Sac: A Randomized Controlled Study
Lead Sponsor:
Zhongshan Ophthalmic Center, Sun Yat-sen University
Conditions:
Primary Acquired Nasolacrimal Duct Obstruction
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Primary acquired nasolacrimal duct obstruction (PANDO) is a lacrimal duct obstruction disease characterized by inflammatory fibrosis of the nasolacrimal duct, with primary symptoms including epiphora ...
Eligibility Criteria
Inclusion
- Patients diagnosed with small lacrimal sac-type PANDO based on clinical symptoms, lacrimal duct irrigation, and CT lacrimal duct angiography (minimum diameter on lacrimal sac angiography ≤3 mm);
- Patients aged 18 years or older;
- Patients with no history of drug allergies (including 5-FU, contrast agents, or other substances that may affect participation in this study);
- Patients who have provided informed consent and signed the informed consent form.
Exclusion
- Previously underwent nasolacrimal duct surgery;
- Nasolacrimal duct obstruction secondary to facial surgery, sinus disease, tumors, trauma, or revision DCR;
- Severe sinusitis or deviated nasal septum;
- Acute dacryocystitis;
- Patients with chronic debilitating conditions such as diabetes, malignant tumors, or malnutrition;
- Patients with systemic diseases such as sarcoidosis or Wegener's granulomatosis that may promote scar formation.
Key Trial Info
Start Date :
September 8 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07154121
Start Date
September 8 2025
End Date
July 1 2026
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China, 510060